View Author
patient myeloma bortezomib thalidomide treatment dexamethasone study therapy response trial neuropathy phase survival blood result grade lenalidomide month analysis disease combination group regimen myeloma patients transplantation richardson melphalan cancer response rate novel agents agent prednisone randomized oncol maintenance table signi ef ficacy signi ficantly cell transplantation journal induction high-dose cytogenetic subgroups cyclophosphamide novel outcome impairment incidence british journal bene fit progression event effect factor autologou impact doxorubicin metaphase cytogenetics cycle research bisphosphonate high-dose dexamethasone number follow-up university celgene review downloaded harousseau activity prognostic relapse zoledronic acid apex trial ficacy palumbo ludwig ficantly
10 Most Recent Publications
|
Multiple myeloma treatment strategies with novel agents in 2011: A European perspective
(Article)
Ludwig, H. Beksaç, M. Goldschmidt, H. Harousseau, J-L. Hess, U. Kropff, M. Da Costa, F.L. Louw, V. Magen-Nativ, H. Mendeleeva, L. Nahi, H. Plesner, T. Bladé, J. San Miguel, J. Sonneveld, P. Udvardy, M. Sondergeld, P. Palumbo, A. Cavenagh, J. Cavo, M. Delforge, M. Dimopoulos, M.A. Drach, J. Einsele, H. Facon, T. |
2011-05-06
|
|
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
(Article)
Delforge, M. Bladé, J. Dimopoulos, M.A. Facon, T. Kropff, M. Ludwig, H. Palumbo, A. Damme, P. van San-Miguel, J-F. Sonneveld, P. |
2010-11-01
|
|
Current multiple myeloma treatment strategies with novel agents: A European perspective
(Article)
Ludwig, H. Beksac, M. Goldschmidt, H. Harousseau, J-L. Hess, U. Ketterer, N. Kropff, M. Mendeleeva, L. Morgan, G. Palumbo, A. Plesner, T. San Miguel, J-F. Bladé, J. Shpilberg, O. Sondergeld, P. Sonneveld, P. Zweegman, S. Boccadoro, M. Cavenagh, J. Cavo, M. Dimopoulos, M.A. Drach, J. Einsele, H. Facon, T. |
2010-02-05
|
|
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma
(Article)
Vogl, D.T. Stadtmauer, E.A. Anderson, K.C. Richardson, P.G. Sonneveld, P. Schuster, M.W. Irwin, D. Facon, T. Harousseau, J-L. Boral, A.L. Neuwirth, R. |
2009-11-01
|
|
The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network
(Article)
Terpos, E. Sezer, O. Dimopoulos, M.A. Facon, T. Macro, M. Waage, A. Sonneveld, P. Croucher, P.I. Garcia-Sanz, R. Boccadoro, M. San Miguel, J-F. Ashcroft, J. Blade, J. Cavo, M. Delforge, M. |
2009-10-01
|
|
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline
(Article)
Richardson, P.G. Sonneveld, P. Bladé, J. Boccadoro, M. Cavenagh, J. Boral, A.L. Esseltine, D-L. Wen, P.Y. Amato, A.A. Anderson, K.C. San Miguel, J-F. Schuster, M.W. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. Goldschmidt, H. Reece, D. |
2009-03-01
|
|
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
(Article)
Niesvizky, R. Richardson, P.G. Harousseau, J-L. Boral, A.L. Esseltine, D-L. Anderson, K.C. Bladé, J. Rajkumar, S.V. Coleman, M. Rosiñol, L. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. |
2008-10-01
|
|
Thalidomide for treatment of multiple myeloma: 10 years later
(Article)
Palumbo, A. Facon, T. Boccadoro, M. Harousseau, J-L. Sonneveld, P. Bladé, J. Offidani, M. Gay, F. Moreau, P. Waage, A. Spencer, A. Ludwig, H. |
2008-04-15
|
|
Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study
(Article)
San Miguel, J-F. Richardson, P.G. Goldschmidt, H. Reece, D. Bladé, J. Boccadoro, M. Cavenagh, J. Neuwirth, R. Boral, A.L. Esseltine, D-L. Anderson, K.C. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. |
2008-04-01
|
|
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial
(Article)
Richardson, P.G. Sonneveld, P. Reece, D. San Miguel, J-F. Bladé, J. Boccadoro, M. Cavenagh, J. Alsina, M. Rajkumar, S.V. Lacy, M. Jakubowiak, A.J. Dalton, W. Schuster, M.W. Boral, A.L. Esseltine, D-L. Schenkein, D. Anderson, K.C. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. Goldschmidt, H. |
2007-11-15
|
